[DOI] [PMC free article] [PubMed] [Google Scholar] 81.Bain SC, Hansen BB, Hunt B, Chubb B, Valentine WL
#PharmD #clinicalpharmacy #Drugupdate #Obesitymanagement To view or add a comment, sign in Obesity Market is Expected to Witness Significant Growth by 2036 Due to Advancements in GLP-1 Therapies and Expanding Treatment Accessibility | DelveInsight: The obesity market is experiencing substantial transformation driven by the rising global obesity burden, growing awareness regarding obesity as a chronic disease, increasing adoption of GLP-1 receptor agonists, and the emergence of next-generation metabolic therapies
Glucagon receptor agonism increases energy expenditure, potentially amplifying the weight loss effect
Rotate Injection Points: Vary the locations of injections to prevent scar tissue or irritation
The World Health Organization (WHO) recognises obesity as one of the most significant chronic health challenges affecting the adult population [3]